Financial Report: Schering-Plough 3Q

Schering-Plough 3Q

3Q Revenues: $4.5 billion (-2%)

3Q Earnings: $515 million (-16%)

YTD Revenues: $13.5 billion (-4%)

YTD Earnings: $2.0 billion (+43%)

Comments: Pharmaceutical sales in the quarter were $3.5 billion (+6%). Sales of Remicade were up 8% to $608 million. Sales of Temodar were $278 million (+2%). Nasonex sales were up 3% to $266 million. Pegintron sales were down 16% to $198 million. Global sales of Clarinex were $164 million (-7%). Prescription Claritin sales were $95 million. Net sales of the cholesterol franchise, which include sales of the cholesterol joint venture plus sales recorded by S-P in non-joint venture territories (such as Japan and Latin America), were $1.1 billion (-5%). R&D expenses were $913 million in the quarter (+2%). For the quarter and YTD, results include $160 million gain on sales of certain divested animal health products associated with the OBS acquisition.